[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
GlobeNewswire
· *Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people..